Cancer-Associated Thrombosis: A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies

References

• Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018;72(2):89–93. doi:10.1016/j.jjcc.2018.02.011
   PubMed Web of Science ®Google Scholar
• Schorling RM, Pfrepper C, Golombek T, et al. Evaluation of biomarkers for the prediction of venous thromboembolism in ambulatory cancer patients. Oncol Res Treat. 2020;43(9):414–427. doi:10.1159/000508271
   PubMed Web of Science ®Google Scholar
• Fernandes CJ, Morinaga LTK, Alves JL, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev. 2019;28(151):1–11. doi:10.1183/16000617.0119-2018
   Web of Science ®Google Scholar
• Khorana AA. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol. 2009;20(10):1619–1630. doi:10.1093/annonc/mdp068
   PubMed Web of Science ®Google Scholar
• Rossel A, Robert-Ebadi H, Marti C. Preventing venous thromboembolism in ambulatory patients with cancer: a narrative review. Cancers. 2020;12(3):1–14. doi:10.3390/cancers12030612
   Web of Science ®Google Scholar
• Kakkos SK, Arnaoutoglou E, Tsolakis IA, et al. Frequency and predictors of chemotherapy-associated venous thromboembolism: the prospective PREVENT study. Int Angiol. 2020;39(2):112–117. doi:10.23736/S0392-9590.20.04272-8
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW. Risk prediction of cancer-associated thrombosis: appraising the first decade and developing the future. Thromb Res. 2018;164(January):S70–S76. doi:10.1016/j.thromres.2018.01.036
   PubMed Web of Science ®Google Scholar
• Barrett CD, Moore HB, Yaffe MB, Moore EE. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: a comment. J Thromb Haemost. 2020;0–1. doi:10.1111/jth.14860
   Web of Science ®Google Scholar
• Key NS, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update summary. J Oncol Pract. 2019;15(12):661–665. doi:10.1200/JOP.19.00368
   Web of Science ®Google Scholar
• Khorana A, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy- associated thrombosis. Blood. 2008;111(10):4902–4907. doi:10.1182/blood-2007-10-116327
   PubMed Web of Science ®Google Scholar
• Mulder FI, Candeloro M, Kamphuisen PW, et al. The khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277–1287. doi:10.3324/haematol.2018.209114
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–719. doi:10.1056/nejmoa1814468
   PubMed Web of Science ®Google Scholar
• Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–728. doi:10.1056/nejmoa1814630
   PubMed Web of Science ®Google Scholar
• Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol Theory Pract. 2005;8(1):19–32. doi:10.1080/1364557032000119616
   Google Scholar
• Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5(69):1–9. doi:10.1017/cbo9780511814563.003
   PubMed Web of Science ®Google Scholar
• Snyder PB, Groebner RJ, Leonard AW, Osborne TH, Wilson HR. Development and validation of a predictive model for. Phys Plasmas. 2009;16(5):4902–4908. doi:10.1063/1.3122146
   Web of Science ®Google Scholar
• Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–5382. doi:10.1182/blood-2010-02-270116
   PubMed Web of Science ®Google Scholar
• Pabinger I, van Es N, Heinze G, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018;5(7):e289–e298. doi:10.1016/S2352-3026(18)30063-2
   PubMed Web of Science ®Google Scholar
• van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102(9):1494–1501. doi:10.3324/haematol.2017.169060
   PubMed Web of Science ®Google Scholar
• Di Nisio M, van Es N, Rotunno L, et al. Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. J Thromb Thrombolysis. 2019;48(1):125–133. doi:10.1007/s11239-019-01845-6
   PubMed Web of Science ®Google Scholar
• Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low–molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33(18):2028–2034. doi:10.1200/JCO.2014.55.1481
   PubMed Web of Science ®Google Scholar
• Cella CA, Di Minno G, Carlomagno C, et al. Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV Study. Oncologist. 2017;22(5):601–608. doi:10.1634/theoncologist.2016-0246
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Taher A, Abdel‐Razeq H, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS–Cancer‐Associated Thrombosis Study. Oncologist. 2017;22(10):1222–1231. doi:10.1634/theoncologist.2016-0414
   PubMed Web of Science ®Google Scholar
• Rupa-Matysek J, Lembicz M, Rogowska EK, Gil L, Komarnicki M, Batura-Gabryel H. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients. Med Oncol. 2018;35:5. doi:10.1007/s12032-018-1120-9
   Web of Science ®Google Scholar
• Gerotziafas GT, Spyropoulos AC, Syrigos K, et al. First external validation of the new COMPASS-CAT risk assessment model for ambulatory patients with breast, colorectal, lung or ovarian cancer. Thromb Res. 2018;164:S232. doi:10.1016/j.thromres.2018.02.111
   Web of Science ®Google Scholar
• Syrigos K, Grapsa D, Sangare R, et al. Prospective assessment of clinical risk factors and biomarkers of hypercoagulability for the identification of patients with lung adenocarcinoma at risk for cancer‐associated thrombosis: the Observational ROADMAP‐CAT Study. Oncologist. 2018;23(11):1372–1381. doi:10.1634/theoncologist.2017-0530
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Eldredge JB, Anand LN, et al. External validation of a venous thromboembolic risk score for cancer outpatients with solid tumors: the COMPASS‐CAT venous thromboembolism risk assessment model. Oncologist. 2020;25(7):1–8. doi:10.1634/theoncologist.2019-0482
   PubMed Web of Science ®Google Scholar
• Martín AJM, Ortega I, Font C, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118(8):1056–1061. doi:10.1038/s41416-018-0027-8
   PubMed Web of Science ®Google Scholar
• Rojas-Hernandez CM, Tang VK, Sanchez-Petitto G, Qiao W, Richardson M, Escalante C. Development of a clinical prediction tool for cancer-associated venous thromboembolism (CAT): the MD Anderson cancer center CAT model. Support Care Cancer. 2020;28(8):3755–3761. doi:10.1007/s00520-019-05150-z
   PubMed Web of Science ®Google Scholar
• Srikanthan A, Tran B, Beausoleil M, et al. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol. 2015;33(6):582–587. doi:10.1200/JCO.2014.58.6537
   PubMed Web of Science ®Google Scholar
• Santi RM, Ceccarelli M, Bernocco E, et al. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas: a pooled-data analysis of 12 clinical trials of fondazione italiana linfomi (FIL). Thromb Haemost. 2017;117(8):1615–1621. doi:10.1160/TH16-11-0895
   Web of Science ®Google Scholar
• Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost. 2016;14(9):1773–1778. doi:10.1111/jth.13378
   PubMed Web of Science ®Google Scholar
• Tully CM, Apolo AB, Zabor EC, et al. The high incidence of vascular thromboembolic events in advanced urothelial cancer treated with platinum chemotherapy agents. Cancer. 2016;122(5):712. doi:10.1002/cncr.29801
   PubMed Web of Science ®Google Scholar
• Zhu Q, Li J, Yan JJ, Huang L, Wu MC, Yan YQ. Predictors and clinical outcomes for spontaneous rupture of hepatocellular carcinoma. World J Gastroenterol. 2012;18(48):7302–7307. doi:10.3748/wjg.v18.i48.7302
   PubMed Web of Science ®Google Scholar
• Li A, Kuderer NM, Garcia DA, et al. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: a systematic review and meta-analysis. J Thromb Haemost. 2019;17(12):2141–2151. doi:10.1111/jth.14613
   PubMed Web of Science ®Google Scholar
• Khorana AA, Vadhan-Raj S, Kuderer NM, et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial. Thromb Haemost. 2017;117(11):2135–2145. doi:10.1160/TH17-03-0171
   PubMed Web of Science ®Google Scholar
• Kimpton M, Wells PS, Carrier M. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: rational and design of the AVERT trial. Thromb Res. 2018;164(Suppl):S124–S129. doi:10.1016/j.thromres.2018.01.018
   PubMed Web of Science ®Google Scholar
• Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703–2708. doi:10.1182/blood-2008-02-142422
   PubMed Web of Science ®Google Scholar
• Barni S, Labianca R, Agnelli G, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9(1):179. doi:10.1186/1479-5876-9-179
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the protecht score. Intern Emerg Med. 2012;7(3):291–292. doi:10.1007/s11739-012-0784-y
   PubMed Web of Science ®Google Scholar
• Godinho J, Casa‐Nova M, Moreira‐Pinto J, et al. ONKOTEV score as a predictive tool for thromboembolic events in pancreatic cancer—a retrospective analysis. Oncologist. 2020;25(2):284–290. doi:10.1634/theoncologist.2019-0510
   Web of Science ®Google Scholar
• Salla E, Dimakakos EP, Tsagkouli S, et al. Venous thromboembolism in patients diagnosed with lung cancer. Angiology. 2016;67(8):709–724. doi:10.1177/0003319715614945
   PubMed Web of Science ®Google Scholar
• Zhang M, Wu S, Hu C. Do lung cancer patients require routine anticoagulation treatment? A meta-analysis. J Int Med Res. 2020;48(1). doi:10.1177/0300060519896919
   Web of Science ®Google Scholar
• van Es N, Ventresca M, Di Nisio M, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: an individual patient data meta-analysis. J Thromb Haemost. 2020;18(8):1940–1951. doi:10.1111/jth.14824
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Tamimi F, Abdel-Razeq R, et al. Predictors of venous thromboembolism in patients with testicular germ cell tumors: a retrospective study. Clin Appl Thromb. 2021;27. doi:10.1177/10760296211024756
   Web of Science ®Google Scholar
• Bezan A, Posch F, Ploner F, et al. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS One. 2017;12(4). doi:10.1371/journal.pone.0176283
   PubMed Web of Science ®Google Scholar
• Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev. 2019;33:24–32. doi:10.1016/j.blre.2018.06.002
   PubMed Web of Science ®Google Scholar
• Del Principe MI, Del Principe D, Venditti A. Thrombosis in adult patients with acute leukemia. Curr Opin Oncol. 2017;29(6):448–454. doi:10.1097/CCO.0000000000000402
   PubMed Web of Science ®Google Scholar
• Al-Ani F, Wang YP, Lazo-Langner A. Development of a clinical prediction rule for venous thromboembolism in patients with acute leukemia. Thromb Haemost. 2020;120(2):322–328. doi:10.1055/s-0039-3400303
   PubMed Web of Science ®Google Scholar
• Mitrovic M, Suvajdzic N, Elezovic I, et al. Thrombotic events in acute promyelocytic leukemia. Thromb Res. 2015;135(4):588–593. doi:10.1016/j.thromres.2014.11.026
   PubMed Web of Science ®Google Scholar
• Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood. 2009;113(17):3911–3917. doi:10.1182/blood-2008-08-175745
   PubMed Web of Science ®Google Scholar
• Grace RF, DeAngelo DJ, Stevenson KE, et al. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018;45(2):306–314. doi:10.1007/s11239-017-1597-7
   PubMed Web of Science ®Google Scholar
• Rank CU, Lynggaard LS, Als-Nielsen B, et al. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2020;2020:10. doi:10.1002/14651858.CD013399.pub2
   Web of Science ®Google Scholar
• Kuderer NM, Poniewierski MS, Culakova E, et al. Predictors of venous thromboembolism and early mortality in lung cancer: results from a Global Prospective Study (CANTARISK). Oncologist. 2018;23(2):247–255. doi:10.1634/theoncologist.2017-0205
   PubMed Web of Science ®Google Scholar
• Mirza AS, Yun S, Al Ali N, et al. Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience. Thromb J. 2019;17(1):1–6. doi:10.1186/s12959-019-0202-z
   PubMed Web of Science ®Google Scholar
• Antic D, Milic N, Todorovic M, et al. OC-07 - decoding risk for thromboembolic events in lymphoma patients. Thromb Res. 2016;140(2016):S171. doi:10.1016/s0049-3848(16)30124-4
   PubMed Web of Science ®Google Scholar
• Rupa-Matysek J, Brzeźniakiewicz-Janus K, Gil L, Krasiński Z, Komarnicki M. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. Cancer Med. 2018;7(7):2868–2875. doi:10.1002/cam4.1540
   PubMed Web of Science ®Google Scholar
• Hohaus S, Tisi MC, Bartolomei F, et al. Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization. Blood Cancer J. 2018;8(6):1–4. doi:10.1038/s41408-018-0096-1
   PubMed Web of Science ®Google Scholar
• Bastos-Oreiro M, Ortiz J, Pradillo V, et al. A validation, with new clinical applicability, of a clinical-genetic risk model that predicts thrombosis with high sensitivity in patients with lymphoma. Hematol Oncol. 2019;37:534. doi:10.1002/hon.219_2631
   Google Scholar
• Sanfilippo KM, Wang T-F, Luo S, et al. Predictive ability of the khorana score for venous thromboembolism (VTE) in multiple myeloma (MM). J Clin Oncol. 2018;36(15_suppl):e18733–e18733. doi:10.1200/jco.2018.36.15_suppl.e18733
   Web of Science ®Google Scholar
• Li A, Wu Q, Luo S, et al. Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Cancer Netw. 2019;17(7):840–847. doi:10.6004/jnccn.2018.7273
   PubMed Web of Science ®Google Scholar
• Fotiou D, Sergentanis TN, Papageorgiou L, et al. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results. Blood Cancer J. 2018;8(11). doi:10.1038/s41408-018-0135-y
   Web of Science ®Google Scholar
• Libourel EJ, Klerk CPW, Van Norden Y, et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood. 2016;128(14):1854–1861. doi:10.1182/blood-2016-02-701094
   PubMed Web of Science ®Google Scholar
• Macedo AVS, Ramacciotti E. Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors? Chinese Clin Oncol. 2019;8(Suppl 1):8–10. doi:10.21037/cco.2019.10.01
   PubMed Web of Science ®Google Scholar
• Hohaus S, Bartolomei F, Cuccaro A, et al. Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis. Cancers. 2020;12(5):1–17. doi:10.3390/cancers12051291
   Web of Science ®Google Scholar
• Kirkizlar O, Alp kirkizlar T, Umit EG, et al. The incidence of venous thromboembolism and impact on survival in Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(8):542–547. doi:10.1016/j.clml.2020.02.021
   PubMed Web of Science ®Google Scholar
• Rupa-Matysek J, Gil L, Kaźmierczak M, Barańska M, Komarnicki M. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana risk score. Med Oncol. 2018;35(1):1–8. doi:10.1007/s12032-017-1065-4
   Web of Science ®Google Scholar
• Borchmann S, Müller H, Hude I, Fuchs M, Borchmann P, Engert A. Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials. Ann Oncol. 2019;30(8):1329–1334. doi:10.1093/annonc/mdz168
   PubMed Web of Science ®Google Scholar
• Antic D, Milic N, Nikolovski S, et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol. 2016;91(10):1014–1019. doi:10.1002/ajh.24466
   PubMed Web of Science ®Google Scholar
• IMWG Guidelines On VTE in Myeloma Pts. Int myeloma Fn.
   Google Scholar
• Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-associated venous thromboembolic disease, version 1.2015: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2015;13(9):1079–1095. doi:10.6004/jnccn.2015.0133
   PubMed Web of Science ®Google Scholar
• Sanfilippo KM, Luo S, Wang T-F, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019;94(11):1176–1184. doi:10.1002/ajh.25603
   PubMed Web of Science ®Google Scholar